Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 30 citing articles:

European Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia
Antonio Vita, Wolfgang Gäebel, Armida Mucci, et al.
European Psychiatry (2022) Vol. 65, Iss. 1
Open Access | Times Cited: 88
The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents
Christoph U. Correll, Marco Solmi, Samuele Cortese, et al.
World Psychiatry (2023) Vol. 22, Iss. 1, pp. 48-74
Open Access | Times Cited: 83
The schizophrenia syndrome, circa 2024: What we know and how that informs its nature
Rajiv Tandon, Henry A. Nasrallah, Schahram Akbarian, et al.
Schizophrenia Research (2023) Vol. 264, pp. 1-28
Open Access | Times Cited: 60
Advances in Alzheimer’s disease’s pharmacological treatment
Carlos Elias Conti Filho, Lairane Bridi Loss, Clairton Marcolongo-Pereira, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 52
Cognitive Impairment Associated with Schizophrenia: From Pathophysiology to Treatment
Daniel C. Javitt
The Annual Review of Pharmacology and Toxicology (2022) Vol. 63, Iss. 1, pp. 119-141
Open Access | Times Cited: 66
Corticolimbic circuitry as a druggable target in schizophrenia spectrum disorders: a narrative review
Abigail Gee, Paola Dazzan, Anthony A. Grace, et al.
Translational Psychiatry (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Physiologic Functions and Therapeutic Applications of α7 Nicotinic Acetylcholine Receptor in Brain Disorders
Chien‐Hsing Lee, Shih‐Ya Hung
Pharmaceutics (2022) Vol. 15, Iss. 1, pp. 31-31
Open Access | Times Cited: 25
Cognitive impairment in psychiatric diseases: Biomarkers of diagnosis, treatment, and prevention
Yafen Wang, Weicheng Meng, Zhixin Liu, et al.
Frontiers in Cellular Neuroscience (2022) Vol. 16
Open Access | Times Cited: 19
Effect-Size Deflation with Increasing Sample-Size in Adjunctive Trials for Negative Symptoms in Schizophrenia: A Meta-Analysis and Meta-Regression Across Mechanisms of Action
Joshua T. Kantrowitz, Megan Mayer, Tse‐Hwei Choo, et al.
(2025)
Closed Access
Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape
Preetika Govil, Joshua T. Kantrowitz
CNS Drugs (2025)
Closed Access
Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia
Tanja Veselinović, Irene Neuner
CNS Drugs (2022) Vol. 36, Iss. 8, pp. 819-858
Open Access | Times Cited: 18
An Update on Treatment of Cognitive Impairment Associated with Schizophrenia
William P. Horan, Lauren T. Catalano, Michael F. Green
Current topics in behavioral neurosciences (2022), pp. 407-436
Closed Access | Times Cited: 17
α7 nicotinic acetylcholine receptor in memory processing
Verónica Pastor, Jorge H. Medina
European Journal of Neuroscience (2023) Vol. 59, Iss. 9, pp. 2138-2154
Closed Access | Times Cited: 10
IUPHAR Review on muscarinic M1 and M4 receptors as drug treatment targets relevant to the molecular pathology of schizophrenia.
Brian Dean
Pharmacological Research (2024) Vol. 210, pp. 107510-107510
Open Access | Times Cited: 3
Ginkgo Biloba as a niche theme cognitive enhancer agent, 1420 dokumen of Scopus database. A bibliometric study from 1988 to 2024
ARMAN YURISALDI SALEH, Dwi Arwandi Yogi Saputra, Riezky Valentina, et al.
F1000Research (2025) Vol. 14, pp. 275-275
Open Access
The Role of α7-Nicotinic Acetylcholine Receptors in the Pathophysiology and Treatment of Parkinson’s Disease
Eslam El Nebrisi, Yosra Lozon, Murat Öz
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 3210-3210
Open Access
Advancements in the treatment of Alzheimer's disease: a comprehensive review
Srushti Rajanna, Prajwal Pradeep Gundale, Apoorva Dev Mahadevaiah
Dementia & Neuropsychologia (2025) Vol. 19
Open Access
Increased Metabolic Potential, Efficacy, and Safety of Emerging Treatments in Schizophrenia
Jonathan M. Meyer, Christoph U. Correll
CNS Drugs (2023) Vol. 37, Iss. 7, pp. 545-570
Open Access | Times Cited: 8
Imputed expression of schizophrenia‐associated genes and cognitive measures in patients with schizophrenia
Chiara Fabbri, Gian Marco Leggio, Filippo Drago, et al.
Molecular Genetics & Genomic Medicine (2022) Vol. 10, Iss. 6
Open Access | Times Cited: 8
The Basal Forebrain Cholinergic Nuclei and Their Relevance to Schizophrenia and Other Psychotic Disorders
S. Eickhoff, Léon Franzen, Αλεξάνδρα Κορδά, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 8
The Less Things Change, the More They Remain the Same: Impaired Neural Plasticity as a Critical Target for Drug Development in Neuropsychiatry
Joshua T. Kantrowitz, Daniel C. Javitt
Advances in neurobiology (2024), pp. 801-828
Closed Access | Times Cited: 1
Genetic polymorphism and neuroanatomical changes in schizophrenia
Mihai Gabriel Năstase, Ilinca Vlaicu, Simona Trifu
Romanian Journal of Morphology and Embryology (2022) Vol. 63, Iss. 2, pp. 307-322
Open Access | Times Cited: 7
An α7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine
Joëlle Choueiry, Crystal Blais, Dhrasti Shah, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 4, pp. 381-395
Open Access | Times Cited: 3
Modern synthesis of cognitive enhancers: cholinergic ligands
Fedor V. Ryzhkov, Yuliya E. Ryzhkova, Michaïl N. Elinson, et al.
Russian Chemical Bulletin (2023) Vol. 72, Iss. 4, pp. 819-837
Closed Access | Times Cited: 3
Dose-dependent effects of GAT107, a novel allosteric agonist-positive allosteric modulator (ago-PAM) for the α7 nicotinic cholinergic receptor: a BOLD phMRI and connectivity study on awake rats
Brittany M. Brems, Erin E. Sullivan, Jenna G. Connolly, et al.
Frontiers in Neuroscience (2023) Vol. 17
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top